Quick search:
Content Search
Result Content Research
Result Content Research
1 Scientific Workforce Diversity and Health Disparities Research Programs
2 Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
3 Alzheon to Present at H.C. Wainwright Annual Global Investment Conference on September 13, 2021
4 Luye Pharma enters into an agreement with ESTEVE to commercialize an Alzheimer's Disease Multi-Day Treatment Patch in Spain
5 Associate feature: Beacon of Hope
6 Vivoryon Therapeutics N : Reports H1 2021 Financial Results and Operational Progress
7 Hospices Prepare for Influx of Dementia Patients As WHO Predicts 40% Rise
8 Amydis Receives NIH Grant Award to Develop a Novel Tau Retinal Tracer for Alzheimer's ...
9 FDA Approves Samsung Bioepis and Biogen's BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna)
10 Enterin Announces Appointment of Dr. Roger Mills to Its Board of Directors
11 Biogen (BIIB) Alzheimer's Drug Aduhelm Sees Slow Launch, Stock Down
12 Nanomedicine in Central Nervous System Injury and Repair Market 2021 Overview with Demographic Data and Industry Growth Trends 2028 – Stillwater Current
13 Biogen : FDA Approves Samsung Bioepis and Biogen's BYOOVIZ (SB11), LUCENTIS Biosimilar (ranibizumab-nuna)
14 Tracking the landscape of dementia research and resources
15 Alzheimer's research tool targets underrepresented groups
16 Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL001 in Amyotrophic Lateral Sclerosis (ALS) | Antibodies | News Channels
17 Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy
18 CHMP Recommends VUMERITY® (diroximel fumarate) for Approval
19 Biogen to Present Data from ADUHELM and Alzheimer's Disease
20 Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen
21 NIA director encourages wider use of transformative Alzheimer's research resources
22 Biogen : CHMP Recommends VUMERITY (diroximel fumarate) for Approval in the European Union as a Treatment for Relapsing-Remitting Multiple Sclerosis
23 Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data
24 Prothena (PRTA) gains 0.31% on Moderate Volume September 15
25 Alector to Present New Data from Frontotemporal Dementia and Alzheimer’s Disease Programs at the 2021 Alzheimer’s Association International Conference
26 Division of Neuroscience | National Institute on Aging
27 Passionate about the science of aging? Consider NIA's career opportunities!
28 Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator Expands Its Investments in Digital Biomarkers for Early Alzheimer's Diagnosis
29 Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator Expands Its Investments in Digital Biomarkers for Early Alzheimer's Diagnosis
30 AB Science today announced that an abstract reporting results from its Phase 3 AB09004 study on
31 Does cellular senescence hold secrets for healthier aging?
32 AB Science announced that results from its Phase 3 AB09004 study on mild to moderate Alzheimer's
33 Alzheimer's trial screening data links high amyloid levels with early stage disease
34 Dr. John Haaga, NIA BSR Director, Retires | National Institute on Aging
35 Other Voices: The Alzheimer's emergency
36 Are infections seeding some cases of Alzheimer's disease?
37 Cassava Sciences Announces Initiation of Cognition Maintenance Study in Alzheimer's disease
38 AARP's $60 Million Investment in Dementia Research Continues to Pay Off
39 Research on resilience in stressful times May 27, 2020
40 Cognitive stimulation in the workplace, plasma proteins, and risk of dementia: three analyses of population cohort studies
41 Hackensack Meridian Health and Eisai Inc. Join Forces to Support the Expansion of Alzheimer's Disease Detection and Services for Patients
42 Biogen Inc. (BIIB) CEO Michel Vounatsos Presents at Morgan Stanley 19th Annual Global Healthcare Conference (Transcript)
43 Prothena Presents New Data from Robust Alzheimer's Portfolio at the Alzheimer's Association International Conference 2021
44 The degree of frailty as a translational measure of health in aging
45 The Dementia Discovery Fund Significantly Enhances its Neuroscience R&D Expertise to Support its Portfolio
46 Dr. Ron Kohanski to lead NIA's Division of Aging Biology
47 AB Science announces that Phase 2B/3 study evaluating oral
48 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease Published in Peer-Reviewed Journal, Alzheimer's Research and Th
49 Eisai Presents Breadth of Data Across Neurology Portfolio, Including Alzheimer's Disease, Insomnia and Epilepsy
50 Comparative efficacy of interventions for reducing symptoms of depression in people with dementia: systematic review and network meta-analysis
51 Cassava Sciences Provides Mid-Year Corporate Update, Clinical Development Progress and Announces Guidance on Clinical Data
52 FDA grants accelerated approval for ADUHELM™ as the first
53 Anavex Life Sciences Reports ANAVEX®2-73 (blarcamesine) featured as a Disease-Modifying Small Molecule in Phase 3 Clinical Trials in a New Publication in Medical Journal titled “Future Avenues for Alzheimer's Disease Detection and Therapy”
54 Cassava Sciences Announces Significant Program Progress and
55 Continuing to stretch the boundaries of biology May 05, 2021
56 Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis
57 Peer-Reviewed Scientific Publication Demonstrates Central Role of Neurotoxic Soluble Amyloid Oligomers in Driving Alzheimer's Pathogenesis
58 Got $2,500? Check Out These 3 Alzheimer's Therapy Stocks
59 Covid-19 linked with Alzheimer's disease-like cognitive impairment, finds study
60 Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine)
61 The Alzheimer's Drug Discovery Foundation Appoints Karen Harris, Chief Financial Officer, and Dr. Mark Forman, Senior Director of Drug Development
62 Merck, Evidation join forces on Alzheimer's data solutions
63 Large-scale brain epigenetics study provides new insights into dementia
64 Ault Global Holdings Announces That Alzamend Neuro Has Submitted an IND Application for AL001 for Dementia Related to Alzheimer’s Disease
65 Alector Reports Second Quarter 2021 Financial Results
66 Prothena to Present Data from Two of its Alzheimer's Disease Programs at the Alzheimer's Association International
67 FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical TrialsADUHELM should be initiated in patients with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's dementia
68 Italfarmaco Group Enters Into an Agreement with Luye Pharma to Commercialize Alzheimer's Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Four European Countries
69 Anavex Life Sciences Reports New Publication in Medical Journal Elucidating the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) related to the Treatment of Alzheimer's Disease
70 Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer’s Disease with Vascular Pathology at the Alzheimer’s Association International Conference 2021 (AAIC)
71 Alector Provides 2021 Corporate Portfolio Update
72 Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer’s Pursuant to the Securities Purchase Agreement with Digital Power Lending
73 Cassava Sciences to Present New Clinical Dataset at 2021 Alzheimer’s Association International Conference
74 ||Playing Virtual Reality Video Game May Boost Seniors' Memory
75 Hope at Lilly after years of Alzheimer's failures
76 Alzheimer's disease beyond amyloid: strategies for future therapeutic interventions
77 Biogen Announces Topline Results From Phase 2 Study of
78 Alzheimers Day 2021: What types of memories are forgotten in this disease
79 Alzheon Completes Patient Enrollment in Phase 2 Biomarker Trial of ALZ-801 Oral Tablet in APOE4 Carriers with Alzheimer's Disease
80 Neuroimaging identifies early-stage dysfunction of the blood–brain barrier – Physics World
81 Alector Reports 2021 First Quarter Financial Results and Provides Business Update
82 AB Science communicates the results from phase 2B/3 study
83 Weekly physical activity may help prevent mild cognitive impairment conversion to dementia
84 Biogen and Eisai Announce Design of ADUHELM ICARE AD-US
85 Could COVID delirium bring on dementia?
86 Athira Pharma to Present ATH-1017 Phase 1 Translational Data at the Alzheimer’s Association International Conference 2021 (AAIC)
87 How Financial Advisors Are Becoming Financial Caregivers
88 Grifols takes another step in the fight against Alzheimer's, partners with Ace to open first AMBAR® Center in Barcelona
89 FDA calls for investigation into industry influence during Alzheimer's drug approval
90 Novel PET tracer sheds light on plaque formation in Alzheimer's disease – Physics World
91 Neuropathix, Inc. Appoints Michael Ropacki, PhD to the Company's Scientific Advisory Board
92 3 Biotech Neurology Stocks Pursuing Alzheimer's And Parkinson's Diseases
93 New Roche data at 2021 AAN highlight impact and breadth of
94 Achieving person-centred dementia care through a bio-psychosocial model
95 New strategy for recruitment and participation in Alzheimer's disease clinical trials
96 Lilly and Banner Alzheimer's Institute collaborate on planned Phase 3 prevention trial of donanemab
97 UF, Scripps Research announce talks to integrate The school walked back its initial masking directive.
98 Late-Breaking AAIC Presentation Explores Potential Clinical Effects Of Lecanemab (BAN2401)
99 ProMIS Neurosciences appoints renowned neuroscientist, Dr. Rudolph Tanzi, as Chair of Scientific Advisory Board
100 Alector Presents 12-Month Results from the INFRONT-2 Phase 2 Open-label Clinical Study of AL001 for the Treatment of Symptomatic Frontotemporal Dementia Patients with a Progranulin Mutation